Hydroxychloroquine shortages during the COVID-19 pandemic

Mendel, Arielle; Bernatsky, Sasha; Thorne, John; Lacaille, Diane; Johnson, Sindhu R.; Vinet, Évelyne

doi:10.1136/annrheumdis-2020-217835

Cited by 35 publications

(38 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…241 Similarly, a national survey to Canadian rheumatologists in April, 2020 found that 50-94% of respondents, depending on the region, had been contacted by pharmacies or patients regarding difficulties accessing HCQ. 242 In a patient-centered study in Germany, 70% of 369 respondents expressed concerns about being unable to receive HCQ prescriptions, and 9% had already reduced their HCQ dose in an attempt to overcome potential drug supply issues. 243 One of the main concerns that HCQ shortages prompted was the risk of SLE flares, which are known to occur as soon as D 1 8 7 X X2 weeks after drug discontinuation for most patients with SLE, especially in the younger SLE population.…”

Section: Ancestral Background Socioeconomic Factors and Indirect Conmentioning

confidence: 99%

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Fernández-Ruiz

Paredes

Niewold

2021

Translational Research

View full text Add to dashboard Cite

As the world navigates the Coronavirus disease 2019 (COVID-19) pandemic, there is a growing need to assess its impact in patients with autoimmune rheumatic diseases, such as systemic lupus erythematosus (SLE). Patients with SLE are a unique population when considering the risk of contracting COVID-19 and infection outcomes. The use of systemic glucocorticoids and immunosuppressants, and underlying organ damage from SLE are potential susceptibility factors. Most patients with SLE have evidence of high type I IFN activity, which may theoretically act as an antiviral line of defense or contribute to the development of a deleterious hyperinflammatory response in COVID-19. Other immunopathogenic mechanisms of SLE may overlap with those described in COVID-19, and thus studies in SLE could provide some insight into immune responses occurring in severe cases of the viral infection. We reviewed the literature to date on COVID-19 in patients with SLE and provide an in-depth review of current research in the area, including immune pathway activation, epidemiology, clinical features, outcomes, and the psychosocial impact of the pandemic in those with autoimmune disease.

show abstract

Section: Ancestral Background Socioeconomic Factors and Indirect Conmentioning

confidence: 99%

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Fernández-Ruiz

Paredes

Niewold

2021

Translational Research

View full text Add to dashboard Cite

show abstract

“…2 We previously reported that rheumatologists in most Canadian provinces observed HCQ shortages early in the COVID-19 pandemic. 3 However, data are lacking on the global experience with HCQ access during the pandemic, specifically in SLE.…”

mentioning

confidence: 99%

Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…More than half of respondents taking HCQ reported difficulties accessing their prescription between March and May 2020 (27). Reports of HCQ shortages and concerns about rheumatology patients' access have also been reported in Canada (28) and countries across Europe (2) and the Middle East (29). Although we do not yet know the full extent of the impact that barriers to HCQ access and shortages have had on patients, serious adverse effects can result from withdrawal in patients with SLE, for which HCQ is a cornerstone of treatment (30).…”

Section: 00mentioning

confidence: 99%

Rise and Fall: Hydroxychloroquine and COVID‐19 Global Trends: Interest, Political Influence, and Potential Implications

Englund

Kinlaw

Sheikh

2020

ACR Open Rheumatology

View full text Add to dashboard Cite

Objective The coronavirus disease 2019 (COVID‐19) pandemic has led to rapid research and reporting on potential preventatives and treatments for the disease, including the drug hydroxychloroquine (HCQ). Despite a lack of robust evidence to support the use of HCQ for treatment of COVID‐19, it was publicly endorsed and received widespread media coverage and public interest. The purpose of this report is to describe and contextualize the surges in public interest, demand, and adoption of HCQ for treatment of COVID‐19 and outline implications for future public health policy and practice. Methods Using national and global events and Google Trends data as a measure of public interest, we describe the timeline and trends in the emergence of, interest in, and adoption of HCQ as a treatment of COVID‐19. We additionally review reports on public demand for HCQ for treatment of COVID‐19 and impacts on medication access among patients with indicated uses. Results Public interest and demand for HCQ surged in the United States and globally following endorsements from public officials and enaction of policies to facilitate off‐label use of HCQ for treatment of COVID‐19. Surges in demand for HCQ led to multiple documented shortages and barriers to accessing HCQ treatment for patients with indicated uses for HCQ. Although there have been reversals in policies to support HCQ use for treatment of COVID‐19 in some regions, others have continued or expanded recommended uses. Conclusion Insights from the global response to HCQ and COVID‐19 can be used to inform prudent decision‐making in the future to prevent premature action and promote informed and equitable responses to promote public health.

show abstract

Hydroxychloroquine shortages during the COVID-19 pandemic

Cited by 35 publications

References 3 publications

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease

Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Rise and Fall: Hydroxychloroquine and COVID‐19 Global Trends: Interest, Political Influence, and Potential Implications

Contact Info

Product

Resources

About